China: First PRC stem cell clinical research rule

Last Updated: 31 August 2015
Article by Huang Jianwen

The National Health and Family Planning Commission (the "NHFPC") and the China Food and Drug Administration (the "CFDA") recently jointly published the Administration Measures for the Research (for Trial Implementation) (the "Administration Measures"), which became effective on 20 July 2015.

The Administration Measures state that the Research (the "Research") must comply with the principles of science, standardization, openness, ethics, and sufficient protection of the rights of research subjects. The Administration Measures also stipulate the qualifications and duties of the Research institutions, the review and record filing mechanism of the Research projects, the regulatory measures for the Research, and the protection of the rights of the Research subjects. Meanwhile, upon the promulgation of the Administration Measures, technologies related to stem cell treatment will no longer be regulated as class III medical technologies. It is worth noticing that Research accomplished under the Administration Measures cannot directly enter into clinical application.

Clarifying the duties and conditions of the Research institutions

Under the Administration Measures, the medical institutions conducting the Research (the "Institutions") are the Research institutions. They are responsible for the quality management of stem cell reagents and clinical research. The responsibilities and duties that must be performed by the Institutions during the Research include initial review, registration/record filing, supervision of the process, quality management and risk management throughout the full process of the preparation of stem cell reagents and clinical research. In the event that an Institution fails to effectively fulfill its duties, the regulatory authorities may suspend the stem cell clinical research project, require rectification within a time limit, or circulate a notice of criticism, among other penalties pursuant to law.

An Institution must: be a Grade III, Level A hospital with diagnostic and treatment specialties corresponding to the Research; lawfully acquire the relevant professional qualifications for a pharmaceutical clinical trial institution; possess comprehensive medical treatment, teaching and scientific research capacities with legal, stable and sufficient research funds; and have a quality control mechanism, persons with the relevant qualifications in charge of the project, authorized reagent quality personnel and research personnel, academic committee and ethics committee mechanisms, and measures for preventing risks and handling adverse reactions and events.

Establishing the initial review, record filing mechanism and the research reporting system of projects

The Administration Measures set out that the clinical research of stem cells shall comply with the requirements of Good Clinical Practices. In addition, the Research must have a sufficient scientific basis and the disease prevention or treatment results must exceed the results from current measures or they must be able to be applied to diseases without current effective intervention measures, or diseases which threaten lives and severely affect the quality of life, or major medical and health care demands.

The Administration Measures establish the project initial review and record filing mechanism. The Institution's academic committee is responsible for conducting a scientific review of record filing materials of the Research application, while the Institution's ethics committee conducts an independent ethical review of the project. The principal personnel of the Institution will review those projects which have already passed the above reviews. A project that has been set up must be filed with China's information system for medical research registration and record filing. The provincial health administration and the food and drug administration will jointly review the project materials and file with the NHFPC and the CFDA. After the research plan has been reviewed and filed for record, the Institution must supervise the researchers so that the researchers strictly comply with the research plan during the clinic research project. The original records of all materials must have electronic copies and must be kept for 30 years after the completion of the clinic research.

Meanwhile, the Administration Measures establish the research reporting mechanism, which requires Institutions to promptly report to the national and provincial health administration and the food and drug administration in cases of severe adverse reactions, errors or accidents. Moreover, the Administration Measures also contain handling and rectification measures. In addition, the Administration Measures also provide that for Research that has been filed for record, any research progress must be reported in accordance with the annual report. The Research outcomes must be reported upon the completion of each stage of the Research.

Respect and protect the rights of the research subjects

The Administration Measures set forth that to effectively protect the rights of the research subjects, the Institution shall establish a sound mechanism to effectively control and manage risks. For high-risk projects, effective measures must be taken for key supervision and administration responsibilities. Third-party insurance shall also be purchased to cover treatment costs and the corresponding economic compensation for damages or death to research subjects related to the Research.

To protect the research subjects' right of informed consent, the Administration Measures stipulate that the research personnel of the Research must perform the obligation to inform the donors and the research subjects about the purpose, significance, content, the expected benefits, and the potential risks of the Research that they will participate in with plain, articulate and accurate language. The informed consent letter must be signed under the signatory's free will. If a severe adverse event occurs to a research subject during the Research process, research personnel must immediately suspend the clinical research and render prompt and appropriate treatment to the research subject.

The Administration Measures are China's first normative document on administrating stem cell clinical research. Its promulgation is of great significance to the promotion of the sound and orderly development of such research, and to promotion of sufficient and effective protection of research subjects.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions